ANTIEMETICS: NEUROTRANSMITTER RECEPTOR BINDING PREDICTS THERAPEUTIC ACTIONS

Stephen J. Peroutka; Solomon H. Snyder

doi:10.1016/S0140-6736(82)92206-1

ANTIEMETICS: NEUROTRANSMITTER RECEPTOR BINDING PREDICTS THERAPEUTIC ACTIONS

Stephen J. Peroutka, Solomon H. Snyder

School of Medicine

Research output: Contribution to journal › Article › peer-review

159 Scopus citations

Abstract

Neurotransmitter receptor binding studies indicate that effective antiemetic drugs potently block histamine H₁, muscarinic cholinergic, or dopamine D₂ receptors. Drug combinations affecting more than one of these receptors appear more clinically efficacious. Designing individual drugs or combinations that influence these three receptors may provide improved emesis control.

Original language	English (US)
Pages (from-to)	658-659
Number of pages	2
Journal	The Lancet
Volume	319
Issue number	8273
DOIs	https://doi.org/10.1016/S0140-6736(82)92206-1
State	Published - Mar 20 1982

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1016/S0140-6736(82)92206-1

Cite this

@article{1ad8d14f36c04c2d91080550e9211c50,

title = "ANTIEMETICS: NEUROTRANSMITTER RECEPTOR BINDING PREDICTS THERAPEUTIC ACTIONS",

abstract = "Neurotransmitter receptor binding studies indicate that effective antiemetic drugs potently block histamine H1, muscarinic cholinergic, or dopamine D2 receptors. Drug combinations affecting more than one of these receptors appear more clinically efficacious. Designing individual drugs or combinations that influence these three receptors may provide improved emesis control.",

author = "Peroutka, {Stephen J.} and Snyder, {Solomon H.}",

note = "Funding Information: NS-16375, a grant of the McKnight Foundation, and an RSA award DA-00074 to S. H. S. Funding Information: This work was supported by U.S.P.H.S. grants MH-18501, DA-00266, and Copyright: Copyright 2014 Elsevier B.V., All rights reserved.",

year = "1982",

month = mar,

day = "20",

doi = "10.1016/S0140-6736(82)92206-1",

language = "English (US)",

volume = "319",

pages = "658--659",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "8273",

}

TY - JOUR

T1 - ANTIEMETICS

T2 - NEUROTRANSMITTER RECEPTOR BINDING PREDICTS THERAPEUTIC ACTIONS

AU - Peroutka, Stephen J.

AU - Snyder, Solomon H.

N1 - Funding Information: NS-16375, a grant of the McKnight Foundation, and an RSA award DA-00074 to S. H. S. Funding Information: This work was supported by U.S.P.H.S. grants MH-18501, DA-00266, and Copyright: Copyright 2014 Elsevier B.V., All rights reserved.

PY - 1982/3/20

Y1 - 1982/3/20

N2 - Neurotransmitter receptor binding studies indicate that effective antiemetic drugs potently block histamine H1, muscarinic cholinergic, or dopamine D2 receptors. Drug combinations affecting more than one of these receptors appear more clinically efficacious. Designing individual drugs or combinations that influence these three receptors may provide improved emesis control.

AB - Neurotransmitter receptor binding studies indicate that effective antiemetic drugs potently block histamine H1, muscarinic cholinergic, or dopamine D2 receptors. Drug combinations affecting more than one of these receptors appear more clinically efficacious. Designing individual drugs or combinations that influence these three receptors may provide improved emesis control.

UR - http://www.scopus.com/inward/record.url?scp=0020041684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020041684&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(82)92206-1

DO - 10.1016/S0140-6736(82)92206-1

M3 - Article

C2 - 6121969

AN - SCOPUS:0020041684

SN - 0140-6736

VL - 319

SP - 658

EP - 659

JO - The Lancet

JF - The Lancet

IS - 8273

ER -

ANTIEMETICS: NEUROTRANSMITTER RECEPTOR BINDING PREDICTS THERAPEUTIC ACTIONS

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this